Radical Radiotherapy has been established as one of the standard of care treatment option in the management of localised and locally advanced prostate cancer. Conventional radiotherapy involves prolonged treatment lasting nearly 8 weeks. Unlike other tumours the alpha/beta ratio for prostate cancer is considered to be as low as 1.5 raising the possibility of superior outcomes with Hypofractionated Radiotherapy. Early trials of Hypofractionation have confirmed the feasibility of delivering relatively safe treatment. With the advent of advanced technology like IMRT and IGRT it is now possible to deliver precision radiotherapy and thus improve the treatment outcomes. A review of all randomised trials will be presented.